Heather Jacene, MD, assistant chief of Nuclear Medicine and Molecular Imaging at Brigham and Women’s Hospital, clinical director of Nuclear Medicine at Dana-Farber Cancer Institute, and associate professor of Radiology at Harvard Medical School in Boston, Massachusetts, has been named president-elect of the Society of Nuclear Medicine and Molecular Imaging (SNMMI). SNMMI introduced a new slate of officers during its 2025 Annual Meeting, held June 21-24 in New Orleans.

A dual-protective approach using botulinum toxin (Botox) alongside an anti-nausea patch significantly reduces salivary gland toxicity in patients with metastatic prostate cancer undergoing PSMA-targeted radiopharmaceutical therapy. The strategy led to a 30 percent decrease in PSMA uptake by the salivary glands without affecting the treatment’s cancer-fighting efficacy. This reduction may enhance treatment adherence and improve overall patient outcomes. The findings were presented at the Society of Nuclear Medicine and Molecular Imaging 2025 Annual Meeting.

Neuroblastoma is a cancer that shows a strange behavior: sometimes it regresses spontaneously, whereas other times it becomes malignant. A team from Nagoya University in Japan identified a previously unknown “uncommitted" neuroblastoma cell state and found that mice presumed to have undergone spontaneous regression exhibited a higher frequency of these uncommitted cells. Gene signatures of the uncommitted cell state were strongly associated with favorable prognosis in human neuroblastoma patients suggesting that understanding these cells could help treat this devastating disease.

City of Hope is using generative artificial intelligence to create operational efficiency, enable AI-driven patient personalization, improve access to clinical trials and empower breakthrough research

Researchers at VCU Massey Comprehensive Cancer Center and the VCU Institute of Molecular Medicine (VIMM) discovered a new and potentially revolutionary way to treat glioblastoma (GBM), the most aggressive type of brain cancer with no curative treatment options. An innovative study – led by Paul B. Fisher, MPh, Ph.D., FNAI, and Swadesh K. Das, Ph.D., and recently published in the Journal for ImmunoTherapy of Cancer – created a novel molecule that demonstrated the capability to introduce a combination of treatment outcomes – direct toxicity and immunotoxicity – to kill the tumor while exploiting immunotherapy to potentially prevent the recurrence of GBM via a “Fusion Superkine” (FSK), containing dual acting therapeutic cytokines in a single molecule.

A multinational team of researchers, co-led by the Garvan Institute of Medical Research, has developed and tested a new AI tool to better characterise the diversity of individual cells within tumours, opening doors for more targeted therapies for patients.